Sectors
PLSE
Pulse Biosciences, Inc.
49.45
2 x 34.91
2 x 61.09
bid
ask
+
1.88
3.95%
02:09 PM
timesize
| Ytd | 260.16% | |
| 1y | 218.21% |
47.57
day range
49.69
12.56
52 week range
50.90
| Open | 48.02 | Prev Close | 47.57 | Low | 47.57 | High | 49.69 | Mkt Cap | 3.54B |
| Vol | 247.80K | Avg Vol | 377.53K | EPS | -1.17 | P/E | N/A | Forward P/E | -41.19 |
| Beta | 1.61 | Short Ratio | 6.66 | Inst. Own | 15.38% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 35.31 | 200-d Avg | 23.13 | 1yr Est | 45.25 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-04 | 2026-09 | -0.35 | N/A | N/A | N/A |
| 2026-08-06 | 2026-06 | -0.31 | -0.36 | -0.05 | -16.13% |
| 2026-05-04 | 2026-03 | -0.32 | -0.27 | 0.05 | 15.62% |
| 2026-02-19 | 2025-12 | -0.26 | -0.26 | 0.01 | 1.89% |
| 2025-11-05 | 2025-09 | -0.31 | -0.29 | 0.02 | 6.45% |
| 2025-08-12 | 2025-06 | -0.26 | -0.28 | -0.02 | -7.69% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-17 | Needham | Upgrade | Buy | |
| 2026-08-10 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-06-04 | Canaccord Genuity | Upgrade | Buy | |
| 2025-07-07 | Oppenheimer | Upgrade | Outperform | |
| 2022-09-21 | Maxim Group | Downgrade | Buy | Hold |
| 2022-05-13 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
Profile
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-12-10 | BARRETT BURKE T | Former | 63.17K | Sale |
| 2026-02-17 | DANAHY KEVIN PATRICK | Officer | 43.30K | Sale |
| 2026-05-10 | DUGGAN ROBERT WILLIAM | Director and Beneficial Owner of more than 10% of a Class of Security | 49.29M | Purchase |
| 2026-05-10 | LAVIOLETTE PAUL A | Chief Executive Officer | 15.85K | Purchase |
| 2024-09-23 | LEVINSON MITCHELL E. | Officer | 0.00 | Conversion of Exercise of derivative security |
| 2025-09-16 | UECKER DARRIN R | Chief Technology Officer | 284.41K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Blackrock Inc. | 1.47M | 69.77M | 2.12% |
| 2026-06-29 | Bank of America Corporation | 1.45M | 68.82M | 2.09% |
| 2026-06-29 | Vanguard Capital Management LLC | 788.64K | 37.52M | 1.14% |
| 2026-06-29 | Portolan Capital Management, LLC | 753.33K | 35.84M | 1.09% |
| 2026-06-29 | Price (T.Rowe) Associates Inc | 748.64K | 35.61M | 1.08% |
| 2026-06-29 | Balyasny Asset Management LP | 718.10K | 34.16M | 1.04% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 590.36K | 28.08M | 0.85% |
| 2026-06-29 | Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 513.04K | 24.41M | 0.74% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 487.18K | 23.18M | 0.70% |
| 2026-05-30 | MFS SERIES TRUST I-MFS New Discovery Fund | 339.45K | 16.15M | 0.49% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 205.44K | 9.77M | 0.30% |
| 2026-05-30 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 178.44K | 8.49M | 0.26% |